Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

197 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Consecutive fecal calprotectin measurements to predict relapse in patients with ulcerative colitis receiving infliximab maintenance therapy.
De Vos M, Louis EJ, Jahnsen J, Vandervoort JG, Noman M, Dewit O, Dʼhaens GR, Franchimont D, Baert FJ, Torp RA, Henriksen M, Potvin PM, Van Hootegem PP, Hindryckx PM, Moreels TG, Collard A, Karlsen LN, Kittang E, Lambrecht G, Grimstad T, Koch J, Lygren I, Coche JC, Mana F, Van Gossum A, Belaiche J, Cool MR, Fontaine F, Maisin JM, Muls V, Neuville B, Staessen DA, Van Assche GA, de Lange T, Solberg IC, Vander Cruyssen BJ, Vermeire SA. De Vos M, et al. Among authors: lambrecht g. Inflamm Bowel Dis. 2013 Sep;19(10):2111-7. doi: 10.1097/MIB.0b013e31829b2a37. Inflamm Bowel Dis. 2013. PMID: 23883959
Early Mucosal Healing Predicts Favorable Outcomes in Patients With Moderate to Severe Ulcerative Colitis Treated With Golimumab: Data From the Real-life BE-SMART Cohort.
Bossuyt P, Baert F, D'Heygere F, Nakad A, Reenaers C, Fontaine F, Franchimont D, Dewit O, Van Hootegem P, Vanden Branden S, Lambrecht G, Ferrante M; Belgian IBD Research and Development Group. Bossuyt P, et al. Among authors: lambrecht g. Inflamm Bowel Dis. 2019 Jan 1;25(1):156-162. doi: 10.1093/ibd/izy219. Inflamm Bowel Dis. 2019. PMID: 29920582 Free article.
Monitoring a Combination of Calprotectin and Infliximab Identifies Patients With Mucosal Healing of Crohn's Disease.
Dreesen E, Baert F, Laharie D, Bossuyt P, Bouhnik Y, Buisson A, Lambrecht G, Louis E, Oldenburg B, Pariente B, Pierik M, van der Woude CJ, D'Haens G, Vermeire S, Gils A. Dreesen E, et al. Among authors: lambrecht g. Clin Gastroenterol Hepatol. 2020 Mar;18(3):637-646.e11. doi: 10.1016/j.cgh.2019.05.029. Epub 2019 May 22. Clin Gastroenterol Hepatol. 2020. PMID: 31128336 Free article. Clinical Trial.
Increasing Infliximab Dose Based on Symptoms, Biomarkers, and Serum Drug Concentrations Does Not Increase Clinical, Endoscopic, and Corticosteroid-Free Remission in Patients With Active Luminal Crohn's Disease.
D'Haens G, Vermeire S, Lambrecht G, Baert F, Bossuyt P, Pariente B, Buisson A, Bouhnik Y, Filippi J, Vander Woude J, Van Hootegem P, Moreau J, Louis E, Franchimont D, De Vos M, Mana F, Peyrin-Biroulet L, Brixi H, Allez M, Caenepeel P, Aubourg A, Oldenburg B, Pierik M, Gils A, Chevret S, Laharie D; GETAID. D'Haens G, et al. Among authors: lambrecht g. Gastroenterology. 2018 Apr;154(5):1343-1351.e1. doi: 10.1053/j.gastro.2018.01.004. Epub 2018 Jan 6. Gastroenterology. 2018. PMID: 29317275 Free article. Clinical Trial.
Preference for a prefilled syringe or an auto-injection device for delivering golimumab in patients with moderate-to-severe ulcerative colitis: a randomized crossover study.
Vermeire S, D'heygere F, Nakad A, Franchimont D, Fontaine F, Louis E, Van Hootegem P, Dewit O, Lambrecht G, Strubbe B, Baert F. Vermeire S, et al. Among authors: lambrecht g. Patient Prefer Adherence. 2018 Jul 6;12:1193-1202. doi: 10.2147/PPA.S154181. eCollection 2018. Patient Prefer Adherence. 2018. PMID: 30013330 Free PMC article.
Infliximab Exposure Associates With Radiologic Evidence of Healing in Patients With Crohn's Disease.
Bossuyt P, Dreesen E, Rimola J, Devuysere S, De Bruecker Y, Vanslembrouck R, Laurent V, Zappa M, Savoye-Collet C, Pariente B, Filippi J, Baert F, D'Haens G, Laharie D, Peyrin-Biroulet L, Vermeire S; TAILORIX study group. Bossuyt P, et al. Clin Gastroenterol Hepatol. 2021 May;19(5):947-954.e2. doi: 10.1016/j.cgh.2020.04.052. Epub 2020 Apr 28. Clin Gastroenterol Hepatol. 2021. PMID: 32360982 Free article.
Steroid-Free Deep Remission at One Year Does Not Prevent Crohn's Disease Progression: Long-Term Data From the TAILORIX Trial.
Laharie D, D'Haens G, Nachury M, Lambrecht G, Bossuyt P, Bouhnik Y, Louis E, Janneke van der Woude C, Buisson A, Van Hootegem P, Allez M, Filippi J, Brixi H, Gilletta C, Picon L, Baert F, Vermeire S, Duveau N, Peyrin-Biroulet L. Laharie D, et al. Among authors: lambrecht g. Clin Gastroenterol Hepatol. 2022 Sep;20(9):2074-2082. doi: 10.1016/j.cgh.2021.11.030. Epub 2021 Nov 26. Clin Gastroenterol Hepatol. 2022. PMID: 34843987 Free article. Clinical Trial.
197 results